Imaging Diagnostic Systems Research Scientist Presents Results on New Imaging Technique
FORT LAUDERDALE, Fla., March 7 -- Imaging Diagnostic Systems, Inc., (BULLETIN BOARD: IMDS) a pioneer in laser optical breast imaging systems, announced that Sergey Telenkov, Ph.D., IDSI Research Scientist, presented an abstract, "Fourier-Domain Methodology for Depth-Selective Photothermoacoustic Imaging of Tissue Chromophores," at the 14th International Conference on Photoacoustic and Photothermal Phenomena in Cairo, Egypt, January 6 - 9, 2007.
Telenkov presented results from a collaborative effort with the University of Toronto, through which a novel imaging modality was developed: a hybrid technology referred to as photothermoacoustic (PTA) imaging. Biomedical applications of PTA methodology have been pursued by numerous research groups over the past decade because of the potentially high-resolution functional imaging capabilities that could result, significantly exceeding those available to purely optical modalities. The team's results demonstrated the attractive features of the FD-PTA technique including high signal-to-noise ratio, depth-selective imaging and excellent axial resolution without high peak-power nanosecond laser exposure.
"My primary research objective as a member of the R&D group at IDSI is the reliable detection of breast cancer. CTLM technology clearly demonstrates the potential to help solve this important problem. However, hybrid techniques such as photothermoacoustic imaging may provide additional advancements to the current imaging modality, especially in terms of spatial resolution," Telenkov explained.
Telenkov's results on FD-PTA imaging will be also presented at the March 2007 meeting of the American Physical Society in Denver, Colorado.
The CTLM® system is a new continuous wave laser breast imaging system that utilizes state-of-the-art technology and patented algorithms to create 3- D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to radiation or require breast compression. In the United States, Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The FDA has determined that the Company's clinical investigation is a non-significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The Imaging Diagnostic Systems CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.
Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com
Photo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO
Source: Imaging Diagnostic Systems, Inc.
CONTACT: Investor Relations, Rick Lutz of LC Group, +1-404-261-1196, lcgroup@mindspring.com, for Imaging Diagnostic Systems, Inc.
Web site: http://www.imds.com/
